Novo Nordisk Launches Wegovy HD as Eli Lilly's $149 GLP-1 Pill Arrives
Two GLP-1 weight-loss drugs launched in the same week -- Novo Nordisk's Wegovy HD injection at $399/month delivers 21% weight loss, while Eli Lilly's Foundayo pill at $149/month offers 12% with the convenience of a daily tablet. Novo Nordisk's stock is down 46% in a year.
Two GLP-1 weight-loss drugs launched within days of each other in the United States, staking out opposite bets on the future of obesity treatment: a more powerful injection versus a cheaper, more convenient pill.
Novo Nordisk's Wegovy HD, a once-weekly semaglutide injection at a new 7.2 mg dose, became available nationwide on April 7 at over 70,000 pharmacies. Two days later, Eli Lilly's Foundayo (orforglipron) -- the first oral GLP-1 pill approved for weight loss -- started shipping on April 9.
The Head-to-Head
| Wegovy HD | Foundayo | |
|---|---|---|
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA approved | March 19, 2026 | April 1, 2026 |
| US launch | April 7 | April 9 |
| Format | Once-weekly injection | Once-daily pill |
| Mean weight loss | 20.7% (72 weeks) | 12.4% at highest dose |
| Self-pay price | $399/month | $149/month |
| With insurance | As low as $25/month | As low as $25/month |
The Efficacy Trade-off
Wegovy HD delivers substantially more weight loss. In the STEP UP trial of approximately 1,400 adults with obesity, semaglutide 7.2 mg produced 20.7% mean body weight reduction over 72 weeks. Nearly one in three patients (31.2%) lost 25% or more of their body weight, and 89% lost at least 5%.
Foundayo's ATTAIN-1 trial enrolled 3,127 participants. At the highest dose, patients lost an average of 12.4% of body weight -- roughly 27 pounds. That is meaningful but about 40% less than Wegovy HD's results.
The trade-off is format. Wegovy HD requires a weekly self-administered injection. Foundayo is a small pill taken once daily at any time, with no food or water restrictions -- a first among GLP-1 treatments.
The Pricing Pressure
Wegovy HD costs $399 per month out of pocket. Foundayo starts at $149. Both offer commercially insured patients rates as low as $25/month, and Foundayo will be available to Medicare Part D beneficiaries at $50/month beginning July 1.
Novo Nordisk is offering its lower Wegovy starting doses at a promotional $199/month through June 30 -- a concession to the pricing pressure bearing down on the company. Generic GLP-1 rivals have already forced Novo Nordisk into price cuts approaching 50% on some products.
The Market's Verdict
Novo Nordisk's stock has been pricing in this competitive shift for months. NVO closed at $37.52 on April 10, down 46% from $69.91 a year earlier and hovering near its 52-week low of $35.13. The shares have fallen 27% since January alone.
The company's own 2026 guidance projects adjusted sales declining 5% to 13% at constant exchange rates.
Wegovy HD's approval came through the FDA's Commissioner's National Priority Voucher pilot program, which compressed the review from a standard 10-to-12 months down to 54 days. The program reflects regulators treating obesity as a national health priority -- but faster approvals benefit all GLP-1 manufacturers, including Novo Nordisk's competitors.
What Patients Get
The simultaneous launches give patients a genuine choice for the first time. Those willing to self-inject weekly can pursue greater weight loss with Wegovy HD. Those who want a pill, need a lower-cost option, or have failed to tolerate injections now have Foundayo.
Wegovy HD is available through NovoCare Pharmacy and nationwide retail pharmacies. Foundayo ships through Eli Lilly's LillyDirect platform and is stocked at retail pharmacies across the country.